Navigation Links
VirtualScopics, Inc. Reports a Record Breaking Quarter
Date:8/12/2009

------ ------- Total assets $7,310,101 $6,861,024 ========== ========== Liabilities and Stockholders' Equity Current liabilities Accounts payable and accrued expenses $984,035 $659,009 Accrued payroll 452,081 554,425 Unearned revenue 609,493 291,594 Derivative liability 1,026,231 - --------- - Total current liabilities 3,071,840 1,505,028 --------- --------- Stockholders' Equity Convertible preferred stock, $0.001 par value; 15,000,000 shares authorized; 8,400 shares designated Series A; issued and outstanding: 3,773 at June 30, 2009, 3,976 at December 31, 2008; liquidation preference $1,000 per share 4 4 6,000 shares designated Series B; issued and outstanding: 4,226 at June 30, 2009 and December 31, 2008; liquidation preference $1,000 per share 4 4 Common Stock, $0.001 par value; 85,000,000 shares authorized; issued and outstanding, 23,758,632 at June 30, 2009 and 23,502,352 at December 31, 2008 23,759 23,503 Additional paid-in capital 13,881,704 16,546,550 Accumulated deficit (9,667,210) (11,214,065) ---------- ----------- Total stockholders' equity 4,238,261 5,355,996 --------- --------- Total liabilities and stockholders' equity $7,310,101 $6,861
'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009
2. BELLUS Health reports results for first half of fiscal 2009
3. China Pharma Holdings, Inc. Reports Second Quarter 2009 Financial Results and Corporate Updates
4. VIVUS Reports Second Quarter 2009 Financial Results
5. Mesa Labs Reports Higher First Quarter Earnings
6. Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block
7. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
8. Winner Medical Reports Third Quarter Fiscal 2009 Results
9. Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
10. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
11. Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 03, 2015 , ... ... and frequently listed among the most influential leaders in healthcare, will offer the ... Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at the ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system ... complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or ... of any given guide RNA (sgRNA or crRNA) to create a break in the ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
... , , , ANNAPOLIS, ... PIP ), a biodefense company developing medical countermeasures against biological ... agreements for the issuance of 2-year, 10% unsecured senior convertible ... private placement of approximately $19.3 million. , , ...
... July 27 Health Robotics today announced,that it has ... to market,implement, and support its I.V. Workflow Engine and ... North America. One of,its software modules (OncoCube) has already ... University of Colorado Hospital [Denver], in,addition to all-digital ...
... , , , ... reveals that adults living in the country,s fifth largest city are ... and complex conditions. Many commonly used therapy classes including drugs to ... have experienced increases in adults 20 and older. , ...
... , Trinitas Comprehensive Cancer Center in Elizabeth, ... chemotherapy program in place , , LOS ... a variety of cancers--along with projections from the National Comprehensive Cancer Network ... by 2013--raise questions for both clinicians and patients with regard to the ...
... COLD SPRING HARBOR, N.Y., July 27 AccuVein LLC, ... illumination device, today announced that its quality system has received ... to customers around the globe AccuVein,s commitment to the quality ... and delivery procedures. , , ...
... , FRANKLIN, Mass., July 27 PLC ... innovative cardiac and vascular medical device-based technologies, today announced it ... capabilities provided by RenalGuard(R) from the Canadian Intellectual Property Office ... patent for RenalGuard in Canada. , , ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2
(Date:9/2/2015)... Sept. 2, 2015 About Duchenne muscular ... disease, which generally affects the male population. It ... The disease is caused due to mutations in ... of production of dystrophin (a protein essential for ... of dystrophin weakens muscle function, causes loss of ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... leukemia is a malignant condition characterized by increased production ... first affects B-lymphocytes and then it can spread to ... mostly at later stages because of the slow buildup ... disease, the malignancy spreads to the spleen, liver, and ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... N.Y., May 8, 2012  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Arthritis Advisory Committee of the U.S. Food and ... (rilonacept) Injection for Subcutaneous Use for the proposed ... patients initiating uric acid-lowering therapy.  The Committee,s recommendation ...
... May 8, 2012 Stereotaxis, Inc. (NASDAQ:   ... to the European market the V-Sono™ intracardiac echocardiography ... Designed to manipulate accessory devices such ... catheters, the Vdrive™ platform combines magnetic navigation with ...
Cached Medicine Technology:Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection 2Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection 3Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection 4Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System 2Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System 3
RCB™ Rotator Cuff Buttress is a completely resorbable plate that will alleviate suture migration in open or mini-Open rotator cuff repairs....
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... an absorbable co-polymer synthesized from all-natural ... glycolic acid. Unlike the homopolymers in ... acid (PLLA) or 100% poly-glycolic acid ... (without crystallinity), meaning that its degradation ...
... Medicine™ AnchorSew™ 3 mm is a resorbable repair ... Medicine ArthroSew suturing device to attach soft tissue ... implanted into a prepared hole in the bone, ... soft tissue anchors are made of a resorbable ...
Medicine Products: